Sugi Predict

Sugi Predict / Compounds / SCHEMBL17420665

SCHEMBL17420665

SCHEMBL17420665

O=c1ccc(I)cn1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.53
▸ BRD2 P25440 1/20 0.53
▸ BRD3 Q15059 1/20 0.53
▸ BRDT Q58F21 1/20 0.53
▸ MKNK1 Q9BUB5 2/20 0.45
▸ MKNK2 Q9HBH9 2/20 0.45
▸ IDH1 O75874 1/20 0.44
▸ F2 P00734 1/20 0.44
▸ PLG P00747 1/20 0.44
▸ ELANE P08246 1/20 0.44
▸ CTSG P08311 1/20 0.44
▸ CMA1 P23946 1/20 0.44
▸ CTRC Q99895 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ PTGDR2 Q9Y5Y4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32665579 0.82 BRD4 (0.40) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL27772274 0.79 MAPT (0.63) BRD4BRD2BRD3BRDTMKNK1
SCHEMBL32665634 0.78 CMA1 (0.51) CMA1ALDH1A1SMN1; SMN2MAPT
SCHEMBL5445259 0.78 MKNK1 (0.58) BRD4BRD2BRD3BRDTMKNK1
SCHEMBL29821531 0.78 BRD4 (0.56) BRD4BRD2BRD3BRDTMKNK1
SCHEMBL6429785 0.78 BRD4 (0.53) BRD4BRD2BRD3BRDTMKNK1
SCHEMBL5440272 0.78 BRD4 (0.53) BRD4BRD2BRD3BRDTMKNK1
SCHEMBL266595 0.78 BRD4 (0.56) BRD4BRD2BRD3BRDTMKNK1
SCHEMBL16466424 0.78 BRD4 (0.53) BRD4BRD2BRD3BRDTMKNK1
SCHEMBL19939512 0.78 BRD4 (0.53) BRD4BRD2BRD3BRDTMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111170991-B Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2023-10-31 — — CN disclosed
EP-3594211-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2023-10-25 — — EP disclosed
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2022-12-08 — — US disclosed
US-11241423-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2022-02-08 — — US disclosed
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2020-05-28 — — US disclosed
CN-111170991-A Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2020-05-19 — — CN disclosed
CN-106660991-B Antiproliferative compounds and methods of use thereof 细胞基因公司 2020-03-13 — — CN disclosed
EP-3166937-B1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2019-09-04 — — EP disclosed
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-08-09 — — US disclosed
US-9968596-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2018-05-15 — — US disclosed
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2018-01-25 — — US disclosed
US-9808451-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2017-11-07 — — US disclosed
EP-3166937-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF Celgene Corporation (US) 2017-05-17 — — EP disclosed
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORP (US) 2017-01-12 — — US disclosed
US-9499514-B2 Antiproliferative compounds and methods of use thereof CELGENE CORPORATION (US) 2016-11-22 — — US disclosed
EP-2870153-B1 SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-02 — — EP disclosed
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION 2016-01-14 — — US disclosed
WO-2016007848-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF CELGENE CORPORATION (US) 2016-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387413-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX BRD4 1437/4885BRD2 2882/4885BRD3 2870/4885
US-20170007590-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX BRD4 1437/4885BRD2 2882/4885BRD3 2870/4885
US-11241423-B2 Antiproliferative compounds and methods of use thereof MCL1, MKI67, BAX BRD4 1437/4885BRD2 2882/4885BRD3 2870/4885
US-20200163948-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX BRD4 1437/4885BRD2 2882/4885BRD3 2870/4885
US-20160009683-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX BRD4 1437/4885BRD2 2882/4885BRD3 2870/4885
US-20180021325-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX BRD4 1437/4885BRD2 2882/4885BRD3 2870/4885
US-20180221361-A1 ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF MCL1, MKI67, BAX BRD4 1437/4885BRD2 2882/4885BRD3 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.